VCR-036
/ Vicero Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 24, 2025
Vicero’s Novel Cancer Immunotherapy Demonstrates Dual-Target Precision with Improved Safety Profile
(Businesswire)
- "Vicero, Inc...announced compelling safety and efficacy data for VCR-036, its novel dual-targeting immunotherapy candidate. The findings, which demonstrate the potential of this pentavalent PD-1/CTLA-4 antibody to treat solid tumors, have been selected for late-breaker presentation at the inaugural American Association for Cancer Research Immuno-oncology (AACR IO) Conference...Superior safety profile with 100% survival rate compared to 50% survival with standard combination therapy; Complete tumor regression achieved with 5 mg/kg dosing, with sustained remission after tumor rechallenge; Favorable pharmacokinetics supporting potential dosing of ~1 mg flat subcutaneous dose every 6 weeks in humans; Significantly reduced immune-related adverse events compared to combination pembrolizumab/ipilimumab therapy."
Late-breaking abstract • Preclinical • Solid Tumor
1 to 1
Of
1
Go to page
1